NO300594B1 - Analogifremgangsmåte for fremstilling av polypeptid og fremgangsmåte for fremstilling av T-celler med spesifisitet mot polypeptidet - Google Patents
Analogifremgangsmåte for fremstilling av polypeptid og fremgangsmåte for fremstilling av T-celler med spesifisitet mot polypeptidet Download PDFInfo
- Publication number
- NO300594B1 NO300594B1 NO904919A NO904919A NO300594B1 NO 300594 B1 NO300594 B1 NO 300594B1 NO 904919 A NO904919 A NO 904919A NO 904919 A NO904919 A NO 904919A NO 300594 B1 NO300594 B1 NO 300594B1
- Authority
- NO
- Norway
- Prior art keywords
- hsp65
- iddm
- cells
- mice
- hhsp65
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 54
- 210000001744 T-lymphocyte Anatomy 0.000 title claims description 94
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 46
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 21
- 229920001184 polypeptide Polymers 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title description 8
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims abstract description 19
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims abstract description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000003431 cross linking reagent Substances 0.000 claims description 5
- 238000010382 chemical cross-linking Methods 0.000 claims description 4
- 238000010647 peptide synthesis reaction Methods 0.000 claims description 4
- 230000003436 cytoskeletal effect Effects 0.000 claims description 3
- 230000004048 modification Effects 0.000 claims description 3
- 238000012986 modification Methods 0.000 claims description 3
- 230000002706 hydrostatic effect Effects 0.000 claims description 2
- 101150086609 groEL2 gene Proteins 0.000 abstract description 198
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract description 182
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 abstract description 180
- 102000004169 proteins and genes Human genes 0.000 abstract description 47
- 108090000623 proteins and genes Proteins 0.000 abstract description 47
- 230000008569 process Effects 0.000 abstract description 30
- 210000004369 blood Anatomy 0.000 abstract description 29
- 239000008280 blood Substances 0.000 abstract description 29
- 238000011161 development Methods 0.000 abstract description 28
- 210000002700 urine Anatomy 0.000 abstract description 24
- 238000011282 treatment Methods 0.000 abstract description 21
- 239000000126 substance Substances 0.000 abstract description 8
- 230000003614 tolerogenic effect Effects 0.000 abstract description 8
- 208000024891 symptom Diseases 0.000 abstract description 7
- 230000000977 initiatory effect Effects 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 109
- 239000000427 antigen Substances 0.000 description 70
- 108091007433 antigens Proteins 0.000 description 69
- 102000036639 antigens Human genes 0.000 description 69
- 206010012601 diabetes mellitus Diseases 0.000 description 54
- 235000018102 proteins Nutrition 0.000 description 46
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 43
- 210000002966 serum Anatomy 0.000 description 42
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 28
- 230000001154 acute effect Effects 0.000 description 27
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 27
- 230000002269 spontaneous effect Effects 0.000 description 25
- 238000003556 assay Methods 0.000 description 24
- 230000001363 autoimmune Effects 0.000 description 24
- 238000012360 testing method Methods 0.000 description 21
- 210000004989 spleen cell Anatomy 0.000 description 20
- 108010062580 Concanavalin A Proteins 0.000 description 19
- 230000003053 immunization Effects 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 229940125396 insulin Drugs 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 238000002649 immunization Methods 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 239000008103 glucose Substances 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 230000006378 damage Effects 0.000 description 13
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 239000002953 phosphate buffered saline Substances 0.000 description 13
- 241000282412 Homo Species 0.000 description 12
- 230000028993 immune response Effects 0.000 description 12
- 230000009257 reactivity Effects 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 241000283707 Capra Species 0.000 description 9
- 102000004877 Insulin Human genes 0.000 description 9
- 108090001061 Insulin Proteins 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 210000002950 fibroblast Anatomy 0.000 description 9
- 230000001900 immune effect Effects 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 239000002671 adjuvant Substances 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 208000023275 Autoimmune disease Diseases 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 238000009171 T-cell vaccination Methods 0.000 description 7
- 206010003246 arthritis Diseases 0.000 description 7
- 229940098773 bovine serum albumin Drugs 0.000 description 7
- 230000002163 immunogen Effects 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000007790 solid phase Substances 0.000 description 7
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 6
- 101150031823 HSP70 gene Proteins 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 101150052825 dnaK gene Proteins 0.000 description 6
- 201000002491 encephalomyelitis Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 201000001421 hyperglycemia Diseases 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000001717 pathogenic effect Effects 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 208000009386 Experimental Arthritis Diseases 0.000 description 5
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000009696 proliferative response Effects 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 201000008827 tuberculosis Diseases 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000005784 autoimmunity Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 229940030156 cell vaccine Drugs 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001904 diabetogenic effect Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 210000004153 islets of langerhan Anatomy 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 239000003226 mitogen Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- 229960001052 streptozocin Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 229940104230 thymidine Drugs 0.000 description 3
- 230000001052 transient effect Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 2
- 206010071155 Autoimmune arthritis Diseases 0.000 description 2
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 description 2
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101000987581 Homo sapiens Perforin-1 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 description 2
- 206010040914 Skin reaction Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 125000003277 amino group Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000000306 component Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000003814 drug Chemical class 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000000703 high-speed centrifugation Methods 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000002427 irreversible effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 230000035483 skin reaction Effects 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 1
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 1
- BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108050001186 Chaperonin Cpn60 Proteins 0.000 description 1
- 102000052603 Chaperonins Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- QPCVIQJVRGXUSA-LURJTMIESA-N Gly-Gly-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)CNC(=O)CN QPCVIQJVRGXUSA-LURJTMIESA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 102000006404 Mitochondrial Proteins Human genes 0.000 description 1
- 108010058682 Mitochondrial Proteins Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- NINIDFKCEFEMDL-AKLPVKDBSA-N Sulfur-35 Chemical compound [35S] NINIDFKCEFEMDL-AKLPVKDBSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 102000005840 alpha-Galactosidase Human genes 0.000 description 1
- 108010030291 alpha-Galactosidase Proteins 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000006470 autoimmune attack Effects 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000008576 chronic process Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000009851 immunogenic response Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical group [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/965—Chemistry: molecular biology and microbiology involving idiotype or anti-idiotype antibody
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NO964483A NO304233B1 (no) | 1989-03-14 | 1996-10-22 | Polypeptid og sett for diagnostisering av insulinavhengig diabetes mellitus samt fremstilling av slikt materiale |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32286489A | 1989-03-14 | 1989-03-14 | |
| US07/371,249 US5114844A (en) | 1989-03-14 | 1989-06-26 | Diagnosis and treatment of insulin dependent diabetes mellitus |
| PCT/US1990/001397 WO1990010449A1 (en) | 1989-03-14 | 1990-03-14 | Diagnosis and treatment of insulin dependent diabetes mellitus |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO904919D0 NO904919D0 (no) | 1990-11-13 |
| NO904919L NO904919L (no) | 1991-01-14 |
| NO300594B1 true NO300594B1 (no) | 1997-06-23 |
Family
ID=26983648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO904919A NO300594B1 (no) | 1989-03-14 | 1990-11-13 | Analogifremgangsmåte for fremstilling av polypeptid og fremgangsmåte for fremstilling av T-celler med spesifisitet mot polypeptidet |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US5114844A (fi) |
| EP (1) | EP0417271B1 (fi) |
| JP (3) | JP3165148B2 (fi) |
| AT (1) | ATE174689T1 (fi) |
| AU (1) | AU639456B2 (fi) |
| CA (1) | CA2029861C (fi) |
| DE (1) | DE69032833T2 (fi) |
| FI (1) | FI103976B (fi) |
| NO (1) | NO300594B1 (fi) |
| WO (1) | WO1990010449A1 (fi) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5645998A (en) | 1988-12-13 | 1997-07-08 | University Of Florida Research Foundation | Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus |
| US5762937A (en) * | 1988-12-13 | 1998-06-09 | University Of Florida Research Foundation, Inc. | Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus |
| US6001360A (en) * | 1988-12-13 | 1999-12-14 | University Of Florida | Method and compositions for early detection and treatment of insulin dependent diabetes mellitus |
| US5780034A (en) * | 1989-03-14 | 1998-07-14 | Yeda Research And Development Co. Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents |
| US5114844A (en) * | 1989-03-14 | 1992-05-19 | Yeda Research And Development Co., Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
| GB8919321D0 (en) * | 1989-08-25 | 1989-10-11 | Univ London | Treatment of chronic inflammatory conditions |
| US5427940A (en) * | 1991-06-03 | 1995-06-27 | Board Of Regents, The University Of Texas System | Engineered cells producing insulin in response to glucose |
| GB9007194D0 (en) * | 1990-03-30 | 1990-05-30 | Wellcome Found | Live vaccines |
| US5512447A (en) * | 1990-09-07 | 1996-04-30 | The Regents Of The University Of California | Methods for the diagnosis and treatment of diabetes |
| DE69133393T2 (de) | 1990-09-07 | 2005-06-16 | The Regents Of The University Of California, Oakland | Verfahren zur diagnose und behandlung von diabetes |
| US5998366A (en) * | 1990-09-21 | 1999-12-07 | The Regents Of The University Of California | Method for ameliorating glutamic acid decarboxylase associated autoimmune disorders |
| US5674978A (en) | 1990-09-21 | 1997-10-07 | The Regents Of The University Of California | Peptides derived from glutamic acid decarboxylase |
| US5620686A (en) * | 1990-09-28 | 1997-04-15 | British Technology Group Limited | Antigen-antibody conjugates |
| CA2096975C (en) * | 1990-11-26 | 2003-04-22 | Carl Wu | Cell stress transcriptional factors |
| US5767240A (en) * | 1991-04-22 | 1998-06-16 | The United States Of America As Represented By The Department Of Health And Human Services | Activity-dependent neurotrophic factor |
| US6174862B1 (en) | 1991-04-22 | 2001-01-16 | Ramot University Authority For Applied Research And Industrial Development, Ltd. | Neurotrophic peptides of activity dependent neurotrophic factor |
| CA2103159A1 (en) * | 1991-05-15 | 1992-11-16 | Ake Lernmark | Cloning and expression of human islet glutamic acid decarboxylase autoantigen |
| WO1993009141A1 (en) * | 1991-11-01 | 1993-05-13 | Joslin Diabetes Center | Antigen associated with type i diabetes mellitus |
| AT398495B (de) * | 1992-06-09 | 1994-12-27 | Wick Georg Dr | Diagnose oder vorhersage von atherosklerose |
| IL102687A (en) * | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| WO1994003478A1 (en) * | 1992-07-31 | 1994-02-17 | Immulogic Pharmaceutical Corporation | Sensitive assay for antigens and antibodies and its use to identify rheumatoid arthritis antigen |
| US5420108A (en) * | 1992-09-14 | 1995-05-30 | Shohet; Isaac H. | Method of controlling diabetes mellitus |
| US5872094A (en) * | 1993-01-06 | 1999-02-16 | The General Hospital Corporation | Method for attaching cartilaginous tissue, cartilage matrix protein or link protein to a surface |
| DK0700445T3 (da) * | 1993-06-04 | 2002-05-13 | Whitehead Biomedical Inst | Stressproteiner og anvendelser deraf |
| US7008790B1 (en) | 1993-08-12 | 2006-03-07 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
| US5728385A (en) | 1993-08-12 | 1998-03-17 | Classen Immunotherapies, Inc. | Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae |
| JPH09505588A (ja) | 1993-11-23 | 1997-06-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 多くの細胞外生成物及びそれらの製造法並びに使用 |
| US6752993B1 (en) | 1993-11-23 | 2004-06-22 | The Regents Of The University Of California | Abundant extracellular product vaccines and methods for their production and use |
| US7300660B2 (en) | 1993-11-23 | 2007-11-27 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| US5863742A (en) * | 1994-03-10 | 1999-01-26 | Chiron Diagnostics Corporation | Inhibition of protease activity of human whole blood cell lysates |
| ATE260295T1 (de) * | 1994-03-21 | 2004-03-15 | Univ Utrecht | Peptidfragmente von mikrobiellen stressproteinen und daraus hergestellte pharmazeutische zusammensetzungen für die behandlung und vorbeugung von entzündungserkrankungen |
| US5869058A (en) * | 1994-05-25 | 1999-02-09 | Yeda Research And Development Co. Ltd. | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines |
| US6509165B1 (en) | 1994-07-08 | 2003-01-21 | Trustees Of Dartmouth College | Detection methods for type I diabetes |
| EP0788512B1 (en) * | 1994-07-08 | 1999-03-24 | The Trustees Of Dartmouth College | Proinsulin peptide compounds for detecting and treating type i diabetes |
| WO1996005223A1 (en) * | 1994-08-12 | 1996-02-22 | The Regents Of The University Of California | Abundant extracellular products and methods for their production and use |
| GB9419553D0 (en) * | 1994-09-27 | 1994-11-16 | Univ Bristol | Polypeptides and their use in the treatment of auto-immune disease |
| UA42040C2 (uk) * | 1994-12-21 | 2001-10-15 | Йеда Рісерч Енд Дівелопмент Ко. Лтд | Поліпептид, спосіб діагностики інсулінозалежного цукрового діабету (iddm), що розвинувся або що розвивається (варіанти), набір для діагностики iddm (варіанти), препарат для запобігання або лікування iddm, фармацевтична композиція для профілактики або лікування iddm |
| US6180103B1 (en) | 1994-12-21 | 2001-01-30 | Yeda Research And Development Co., Ltd. | Peptide p277 analogs, and pharmaceutical compositions comprising them for treatment or diagnosis of diabetes |
| IL114407A0 (en) * | 1995-06-30 | 1995-10-31 | Yeda Res & Dev | Novel peptides and pharmaceutical compositions comprising them |
| US20030190323A1 (en) * | 1995-07-05 | 2003-10-09 | Yeda Research And Development Co. Ltd. | Preparations and methods for the treatment of T cell mediated diseases |
| US6488933B2 (en) | 1995-07-05 | 2002-12-03 | Yeda Research And Development Co. Ltd. | Preparations for the treatment of T cell mediated diseases |
| IL114458A0 (en) * | 1995-07-05 | 1995-11-27 | Yeda Res & Dev | Therapeutic preparations for treatment of T cell mediated diseases |
| US6013660A (en) * | 1996-10-02 | 2000-01-11 | The Regents Of The University Of California | Externally targeted prophylactic and chemotherapeutic method and agents |
| US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
| WO1998035705A1 (en) * | 1997-02-18 | 1998-08-20 | Whitehead Institute For Biomedical Research | Use of heat shock proteins to deliver moieties into cells |
| CN100489105C (zh) | 1997-08-05 | 2009-05-20 | 恩温塔生物制药学公司 | 包含hpv抗原和应激蛋白或者其表达载体的组合物激发的抗hpv抗原免疫应答 |
| US20020009448A1 (en) * | 1997-09-19 | 2002-01-24 | Leslie P. Weiner | T-cell vaccination for the treatment of multiple sclerosis |
| WO1999037315A1 (en) * | 1998-01-27 | 1999-07-29 | Bai Jane Pei Fan | Chemical derivatives of autoantigens and autoimmune-suppressive peptides and pharmaceutical composition containing the same |
| US7488476B2 (en) * | 1998-11-05 | 2009-02-10 | Hadasit Medical Research Services & Development Ltd. | B-cell epitope peptides of HSP 65, DNA encoding said peptides, antibodies directed against said peptides and the different uses thereof in the treatment of inflammatory and autoimmune diseases |
| WO2000027870A1 (en) * | 1998-11-05 | 2000-05-18 | Hadasit Medical Research Services & Development Ltd. | Novel amino acid sequences, dna encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof |
| US8158125B2 (en) * | 1998-11-05 | 2012-04-17 | Hadasit Medical Research Services & Development Ltd. | B-cell epitope peptides of HSP 65, novel amino acid sequences, DNA encoding the amino acid sequences of said peptides, antibodies directed against said peptides and different uses thereof in the treatment of inflammatory and autoimmune diseases |
| US6497880B1 (en) | 1998-12-08 | 2002-12-24 | Stressgen Biotechnologies Corporation | Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus |
| AU5926700A (en) * | 1999-07-08 | 2001-01-30 | Stressgen Biotechnologies Corporation | Induction of a th1-like response in vitro |
| IL150113A0 (en) * | 1999-12-15 | 2002-12-01 | Peptor Ltd | Fragments and antagonists of heat shock protein 60 |
| AU1814101A (en) | 2000-01-14 | 2001-07-24 | Massachusetts Institute Of Technology | In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete ATP binding domain and is CD4+ cell-independent |
| IL153474A0 (en) * | 2000-06-26 | 2003-07-06 | Stressgen Biotechnologies Corp | Human papilloma virus treatment |
| IL137460A0 (en) * | 2000-07-24 | 2001-07-24 | Yeda Res & Dev | Identifying antigen clusters for monitoring a global state of an immune system |
| MXPA03006971A (es) * | 2001-02-05 | 2004-05-05 | Stressgen Biotechnologies Corp | Tratamiento del virus de hepatitis b. |
| EP1575479A4 (en) | 2002-01-31 | 2006-10-25 | Develogen Israel Ltd | HSP-PEPTIDES AND ANALOGUES FOR MODULATING IMMUNE RESPONSES ON ANY PRESENTING CELLS |
| US20050084967A1 (en) | 2002-06-28 | 2005-04-21 | Xcyte Therapies, Inc. | Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation |
| CA2595520A1 (en) * | 2004-01-28 | 2005-08-11 | Develogen Israel Ltd. | Hsp therapy in conjunction with a low antigenicity diet |
| US20050260770A1 (en) * | 2004-04-01 | 2005-11-24 | Cohen Irun R | Antigen array and diagnostic uses thereof |
| EP1835933A4 (en) * | 2005-01-04 | 2015-01-07 | Yeda Res & Dev | HSP60, PEPTIDES HSP60 AND T-CELL VACCINES FOR IMMUNOMODULATION |
| EP2402022B1 (en) | 2005-03-14 | 2014-10-29 | Yeda Research And Development Co., Ltd. | Compositions of HSP60 peptides and viral antigens for vaccination and diagnosis |
| CN101277722A (zh) | 2005-08-06 | 2008-10-01 | 王庆华 | 用于预防和治疗ⅰ型糖尿病的组合物及方法 |
| WO2007116409A2 (en) | 2006-04-11 | 2007-10-18 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Improved vaccines comprising multimeric hsp60 peptide carriers |
| DE102006019127A1 (de) * | 2006-04-25 | 2007-10-31 | Carl Zeiss Meditec Ag | Multiwellenlängen-Lasersystem und Verfahren für ophthalmologische Anwendungen |
| WO2009090650A2 (en) | 2008-01-16 | 2009-07-23 | Ben-Gurion University Of The Negev Research And Development Authority | Vaccine for alzheimer's disease |
| JP2015508812A (ja) | 2012-03-01 | 2015-03-23 | イエダ リサーチ アンド ディベロプメント カンパニー リミテッド | 非自己免疫性糖尿病を抑制および処置するためのｈｓｐ６０由来ペプチドおよびペプチド類似体 |
| CN104203263A (zh) | 2012-03-01 | 2014-12-10 | 耶达研究与发展有限公司 | 利用HSP60衍生肽再生胰岛β细胞 |
| EP3090064B1 (en) | 2013-12-31 | 2019-11-13 | Yeda Research and Development Co. Ltd. | Diagnosis of systemic lupus erythematosus using oligonucleotides antigens |
| WO2016139659A1 (en) | 2015-03-01 | 2016-09-09 | Immunarray Ltd. | Diagnosis of systemic lupus erythematosus using protein, peptide and oligonucleotide antigens |
| KR101843000B1 (ko) * | 2016-12-07 | 2018-03-28 | 주식회사 에프앤디파트너스 | 피부 트러블별 미용 또는 치료 기능을 제공하는 개인 맞춤형 기능성 팩 및 그의 사용 방법 |
| KR102292635B1 (ko) | 2019-07-26 | 2021-08-23 | (의)삼성의료재단 | 마스크 팩 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL8701163A (nl) * | 1986-09-09 | 1988-04-05 | Nederlanden Staat | Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. |
| DE3782996T2 (de) * | 1986-09-23 | 1993-06-09 | Yeda Res & Dev | Zellmembranproteine, zubereitungen, die sie enthalten und verfahren zu ihrer herstellung. |
| US4952395A (en) * | 1987-02-26 | 1990-08-28 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
| NL8703107A (nl) * | 1987-12-22 | 1989-07-17 | Nederlanden Staat | Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten. |
| IL85746A (en) * | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
| US5114844A (en) * | 1989-03-14 | 1992-05-19 | Yeda Research And Development Co., Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
-
1989
- 1989-06-26 US US07/371,249 patent/US5114844A/en not_active Expired - Lifetime
-
1990
- 1990-03-14 CA CA002029861A patent/CA2029861C/en not_active Expired - Lifetime
- 1990-03-14 AU AU55467/90A patent/AU639456B2/en not_active Expired
- 1990-03-14 AT AT90908064T patent/ATE174689T1/de not_active IP Right Cessation
- 1990-03-14 WO PCT/US1990/001397 patent/WO1990010449A1/en active IP Right Grant
- 1990-03-14 EP EP90908064A patent/EP0417271B1/en not_active Expired - Lifetime
- 1990-03-14 DE DE69032833T patent/DE69032833T2/de not_active Expired - Lifetime
- 1990-03-14 JP JP50811690A patent/JP3165148B2/ja not_active Expired - Fee Related
- 1990-11-13 NO NO904919A patent/NO300594B1/no not_active IP Right Cessation
- 1990-11-13 FI FI905614A patent/FI103976B/fi active IP Right Grant
-
1993
- 1993-03-29 US US08/039,704 patent/US5671848A/en not_active Expired - Lifetime
-
1999
- 1999-07-26 JP JP21116199A patent/JP3203323B2/ja not_active Expired - Lifetime
-
2000
- 2000-05-29 JP JP2000157825A patent/JP2001010962A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FI905614A0 (fi) | 1990-11-13 |
| FI103976B1 (fi) | 1999-10-29 |
| US5671848A (en) | 1997-09-30 |
| ATE174689T1 (de) | 1999-01-15 |
| CA2029861C (en) | 2001-01-16 |
| EP0417271A1 (en) | 1991-03-20 |
| EP0417271B1 (en) | 1998-12-16 |
| JPH04502920A (ja) | 1992-05-28 |
| US5114844A (en) | 1992-05-19 |
| CA2029861A1 (en) | 1990-09-15 |
| DE69032833T2 (de) | 1999-05-12 |
| NO904919D0 (no) | 1990-11-13 |
| EP0417271A4 (en) | 1992-09-09 |
| JP3203323B2 (ja) | 2001-08-27 |
| AU639456B2 (en) | 1993-07-29 |
| AU5546790A (en) | 1990-10-09 |
| DE69032833D1 (de) | 1999-01-28 |
| NO904919L (no) | 1991-01-14 |
| JP2001010962A (ja) | 2001-01-16 |
| WO1990010449A1 (en) | 1990-09-20 |
| JP2000055916A (ja) | 2000-02-25 |
| FI103976B (fi) | 1999-10-29 |
| JP3165148B2 (ja) | 2001-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO300594B1 (no) | Analogifremgangsmåte for fremstilling av polypeptid og fremgangsmåte for fremstilling av T-celler med spesifisitet mot polypeptidet | |
| US5780034A (en) | Diagnosis and treatment of insulin dependent diabetes mellitus using heat shock protein determinents | |
| Elias et al. | Induction and therapy of autoimmune diabetes in the non-obese diabetic (NOD/Lt) mouse by a 65-kDa heat shock protein. | |
| US5154923A (en) | Polypeptides and derivatives thereof as well as their use in pharmaceutical and diagnostic compositions | |
| Elias et al. | Induction of diabetes in standard mice by immunization with the p277 peptide of a 60‐kDa heat shock protein | |
| US5578303A (en) | Diagnosis and treatment of insulin dependent diabetes mellitus | |
| JP3420245B2 (ja) | ペプチドｐ２７７類似体及びこれを含む糖尿病の治療又は診断のための薬剤組成物 | |
| JP2007000147A (ja) | 微生物ストレスタンパク質のペプチド断片、および該タンパク質もしくは断片の使用 | |
| AU710882B2 (en) | Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits | |
| US6110746A (en) | Peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits | |
| IL94241A (en) | Methods and kits for diagnosis of insulin dependent diabetes mellitus (iddm) | |
| FI104179B (fi) | Menetelmä terapeuttisesti käyttökelpoisen polypeptidin valmistamiseksi | |
| RU2159250C2 (ru) | АНАЛОГИ ПЕПТИДА p277 И СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ И ДИАГНОСТИКИ ДИАБЕТА | |
| MXPA98000191A (en) | Novedous peptides derived from human protein 60 produced by thermal shock, for the treatment of diabetes, compositions, methods and equi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |